The story of Sildenafil presents a challenging picture for investors. While the initial launch generated significant returns, the end of its intellectual property protection opened the floodgates to off-brand https://sidneyimnu388820.theisblog.com/42235257/sildenafil-and-big-pharma-a-precarious-bet